Missed the webinar? Here are Investing.com’s top 10 stock picks for 2026
DUBLIN - J.P. Morgan Securities Plc disclosed Friday its dealings in Avadel Pharmaceuticals plc securities as part of its role as financial advisor to Alkermes plc, according to a regulatory filing with the Irish Takeover Panel.
The filing, made under Rule 38.5(a) of the Irish Takeover Panel Act, shows that on November 25, 2025, the investment bank purchased 1,476 ordinary shares of Avadel Pharmaceuticals at prices ranging from $22.93 to $22.97 per share. The bank also sold 561 shares at $22.97 per share on the same day.
J.P. Morgan Securities is acting as a connected exempt principal trader with recognized intermediary status in a client-serving capacity. The bank confirmed it has no indemnity arrangements, agreements, or understandings relating to options or derivatives regarding the relevant securities.
The disclosure was made in compliance with Irish takeover regulations, which require parties involved in acquisition proceedings to report their dealings in the securities of companies subject to takeover offers.
Avadel Pharmaceuticals, a biopharmaceutical company, is currently the subject of takeover interest from Alkermes plc. The filing indicates the transaction remains in progress, with J.P. Morgan serving as financial advisor to Alkermes in the potential acquisition.
The disclosure was submitted as an amendment to a previous filing, according to the regulatory announcement published today.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.